par Bosly, André;Sonet, Anne;Pinkerton, C Ross;McCowage, Geoffrey;Bron, Dominique 
;Sanz, Miguel A;Van den Berg, Hendrik
Référence Cancer, 98, 5, page (1048-1054)
Publication Publié, 2003-09
;Sanz, Miguel A;Van den Berg, HendrikRéférence Cancer, 98, 5, page (1048-1054)
Publication Publié, 2003-09
Article révisé par les pairs
| Titre: |
|
| Auteur: | Bosly, André; Sonet, Anne; Pinkerton, C Ross; McCowage, Geoffrey; Bron, Dominique; Sanz, Miguel A; Van den Berg, Hendrik |
| Informations sur la publication: | Cancer, 98, 5, page (1048-1054) |
| Statut de publication: | Publié, 2003-09 |
| Sujet CREF: | Sciences bio-médicales et agricoles |
| Mots-clés: | Acute leukemia |
| Compassionate use | |
| Hemodialysis | |
| Hyperuricemia | |
| Non-Hodgkin lymphoma | |
| Rasburicase (Fasturtec®/Elitek®) | |
| Tumor lysis syndrome | |
| MeSH keywords: | Adolescent |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Child | |
| Child, Preschool | |
| Female | |
| Humans | |
| Hyperuricemia -- drug therapy | |
| Hyperuricemia -- etiology | |
| Infant | |
| Infusions, Intravenous | |
| Lymphoma, Non-Hodgkin -- complications | |
| Lymphoma, Non-Hodgkin -- drug therapy | |
| Male | |
| Middle Aged | |
| Recombinant Proteins | |
| Treatment Outcome | |
| Tumor Lysis Syndrome -- drug therapy | |
| Tumor Lysis Syndrome -- etiology | |
| Urate Oxidase -- pharmacology | |
| Urate Oxidase -- therapeutic use | |
| Note générale: | Clinical Trial |
| Journal Article | |
| FLWIN | |
| Langue: | Anglais |
| Identificateurs: | urn:issn:0008-543X |
| info:doi/10.1002/cncr.11612 | |
| info:scp/0041887047 | |
| info:pmid/12942574 |
